Safety of SBC-103 in MPS IIIB patients

• Research type

  Research Study

• Full title

  A Phase I/II Open Label Study In MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of SBC-103 Administered Intravenously and also Sub-Study A Phase I/II Open Label Extension Sub-Study in MPS IIIB Subjects to Evaluate the Long-Term Safety, Efficacy, and Pharmacokinectics of SBC-103 Administered Intravenously

• IRAS ID

  149903

• Contact name

  Suresh Vijay

• Contact email

  Suresh.vijay@bch.nhs.uk

• Sponsor organisation

  Alexion Pharmaceuticals Inc

• Eudract number

  2013-003400-39

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  14/NW/0348

• Date of REC Opinion

  15 Jul 2014

• REC opinion

  Further Information Favourable Opinion